Abstract Supplementary Materials REFERENCES AND NOTES Information & Authors Metrics & Citations Check Access References Figures Tables Media Share This article has 0 eLetter . Abstract Despite the introduction of genome sequencing (GS) for rare disease diagnostics, a genetic cause is not identified in most patients. Here, we explored the potential of proteomics to improve the diagnostic yield in 424 patients with rare diseases from the 100,000 Genomes Project (100kGP) without a genetic diagnosis.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Mark Caulfield
Cardiovascular prescriber attitudes to pharmacogenomics: a survey by the ESC working group on cardiovascular pharmacotherapy
Abstract The aim of this study was to elucidate cardiovascular prescriber access, uptake, and attitudes toward CYP2C19 and CYP2D6 genetic testing to guide prescribing of commonly used medications such as clopidogrel, antiarrhythmics, proton pump inhibitors, and antidepressants. A survey, designed in collaboration with the European Society of Cardiology (ESC) WG on Cardiovascular Pharmacotherapy and external experts was disseminated to ESC members using SurveyMonkey.
Increased frequency of repeat expansion mutations across different populations - Nature Medicine
Abstract Repeat expansion disorders (REDs) are a devastating group of predominantly neurological diseases. Together they are common, affecting 1 in 3,000 people worldwide with population-specific differences. However, prevalence estimates of REDs are hampered by heterogeneous clinical presentation, variable geographic distributions and technological limitations leading to underascertainment.
A Genomics England haplotype reference panel and imputation of UK Biobank - Nature Genetics
Abstract We built a reference panel with 342 million autosomal variants using 78,195 individuals from the Genomics England (GEL) dataset, achieving a phasing switch error rate of 0.18% for European samples and imputation quality of r2 = 0.75 for variants with minor allele frequencies as low as 2 × 10−4 in white British samples.
Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme - Nature Medicine
Abstract The Cancer Programme of the 100,000 Genomes Project was an initiative to provide whole-genome sequencing (WGS) for patients with cancer, evaluating opportunities for precision cancer care within the UK National Healthcare System (NHS). Genomics England, alongside NHS England, analyzed WGS data from 13,880 solid tumors spanning 33 cancer types, integrating genomic data with real-world treatment and outcome data, within a secure Research Environment.
ADRA2A and IRX1 are putative risk genes for Raynaud’s phenomenon - Nature Communications
Abstract Raynaud’s phenomenon (RP) is a common vasospastic disorder that causes severe pain and ulcers, but despite its high reported heritability, no causal genes have been robustly identified. We conducted a genome-wide association study including 5,147 RP cases and 439,294 controls, based on diagnoses from electronic health records, and identified three unreported genomic regions associated with the risk of RP (p < 5 × 10−8).
GWAS of random glucose in 476,326 individuals provide insights into diabetes pathophysiology, complications and treatment stratification - Nature Genetics
|
By Alessia Faggian, Alessia David, Reedik Mägi, Emma Ahlqvist, Gudmar Thorleifsson, Robert Scott, Aaron Isaacs, Christian Gieger, Rona J. Strawbridge, Anuj Goel, Anne Jackson, Heather M. Stringham, Eric Farber-Eger, Valgerdur Steinthorsdottir, André G. Uitterlinden, Patricia B Munroe, Morris Brown, Barbara Thorand, Tom Wilsgaard, Karen L. Mohlke, Zhe Wang, GWA-PA Consortium, Wolfgang Koenig, Inês Barroso, Jaakko Tuomilehto, Michael Boehnke, Mark Caulfield, Nicholas J Wareham, Claudia Langenberg, Grant W. Montgomery, Ioanna Tzoulaki, Paul Elliott, Kari Stefansson, Evan L. Brittain, Mark McCarthy, Philippe Froguel, Leif Groop, Josée Dupuis, James B. Meigs, Giuseppe Deganutti, Yurii S. Aulchenko, Ben Jones, Inga Prokopenko
|
Nature
Verified
Abstract Conventional measurements of fasting and postprandial blood glucose levels investigated in genome-wide association studies (GWAS) cannot capture the effects of DNA variability on ‘around the clock’ glucoregulatory processes. Here we show that GWAS meta-analysis of glucose measurements under nonstandardized conditions (random glucose (RG)) in 476,326 individuals of diverse ancestries and without diabetes enables locus discovery and innovative pathophysiological observations.
Nuclear-embedded mitochondrial DNA sequences in 66,083 human genomes - Nature
Abstract DNA transfer from cytoplasmic organelles to the cell nucleus is a legacy of the endosymbiotic event—the majority of nuclear-mitochondrial segments (NUMTs) are thought to be ancient, preceding human speciation1,2,3. Here we analyse whole-genome sequences from 66,083 people—including 12,509 people with cancer—and demonstrate the ongoing transfer of mitochondrial DNA into the nucleus, contributing to a complex NUMT landscape.
It’s in the genes
Image: Leigh Prather, via Shutterstock Mark Caulfield and John Chisholm argue that the UK must harness the potential of genomics The Covid-19 pandemic has been the most globally disruptive event in decades. A virus for which there is no known cure has revealed how fragile health is in today’s globalised high-tech world. But through developing new vaccines, tracking how the virus evolves and is transmitted, and through repurposing therapies, genomics has come to the rescue.
6 Translating genomics for clinical benefit
FPM Meeting Abstracts 2019 Speaker abstracts 6 Translating genomics for clinical benefit Free Mark Caulfield1,2 1Chief Executive and Chief Scientific Officer, Genomics UK 2Co-Director and Professor of Clinical Pharmacology, William Harvey Research Institute, Barts and the London Abstract The UK 100,000 Genomes Project has focussed on transforming genomic medicine in the National Health Service using whole genome sequencing in rare disease, cancer and infection.
PanelApp crowdsources expert knowledge to establish consensus diagnostic gene panels
A fundamental problem in rare-disease diagnostics is the lack of consensus as to which genes have sufficient evidence to attribute causation. To address this issue, we have created PanelApp (https://panelapp.genomicsengland.co.uk), a publicly available knowledge base of curated virtual gene panels. Fig. 2: PanelApp genome coverage. Fig. 4: PanelApp traffic-light system for evidence level. Data availability PanelApp is a publicly available database.
Genomic medicine: time for health-care transformation
Genomic medicine—the use of genetic information to inform medical care or predict risk of disease—is beginning to transform health care. The first human genome cost about US$3 billion to sequence. , 2 Davies SC Chief Medical Officer Annual Report 2016: generation genome. A whole human genome can now be sequenced for under $1000, and for even less it is possible to read targeted parts of the genome (panels) or the protein coding part (the exome).
NHS England " Genomics
Genomics is the study of the body’s genes, their functions and their influence on the growth, development and working of the body – using a variety of techniques to look at the body’s DNA and associated compounds. The UK is recognised worldwide as a leader in genomics and the unique structure of the NHS is allowing us to deliver these advances at scale and pace for patient benefit.
A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering
Aim: To find new genetic loci associated with statin response, and to investigate the association of a genetic risk score (GRS) with this outcome. Patients & methods: In a discovery meta-analysis (five studies, 1991 individuals), we investigated the effects of approximately 50000 single nucleotide polymorphisms on statin response, following up associations with p < 1 × 10-4 (three independent studies, 5314 individuals). We further assessed the effect of a GRS based on SNPs in ABCG2, LPA and APOE.
Caulfield Company launches new website
The Caulfield Company, based in Harrogate, UK, has launched a new website to mark its recent expansion. Using clean, muted colours and a minimalist layout, the new design is a sophisticated from the previous platform yet remains within a Wordpress CMS, retaining its functionality and ease of use. The site is heavily image based in order to convey the sheer size and scale of the bespoke design projects that can be undertaken by their team throughout the country.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Mark
Contact Mark, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack